Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


28.01.2019

1 Biochem Biophys Res Commun
1 Br J Cancer
2 Cancer Res
1 Curr Opin Oncol
1 Int J Cancer
8 J Am Acad Dermatol
1 J Biol Chem
4 J Surg Oncol
1 Lancet Oncol
4 Melanoma Res
4 Oncogene
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Biochem Biophys Res Commun

  1. JEONG K, Murphy JM, Rodriguez YAR, Kim JS, et al
    FAK inhibition reduces metastasis of alpha4 integrin-expressing melanoma to lymph nodes by targeting lymphatic VCAM-1 expression.
    Biochem Biophys Res Commun. 2019 Jan 16. pii: S0006-291X(19)30058.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. LI WQ, Drucker AM, Cho E, Laden F, et al
    Tetracycline use and risk of incident skin cancer: a prospective study.
    Br J Cancer. 2018;118:294-298.
    PubMed     Text format     Abstract available


    Cancer Res

  3. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
    Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
    PubMed     Text format     Abstract available

  4. YOUNG A, Ngiow SF, Gao Y, Patch AM, et al
    A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
    Cancer Res. 2018;78:1003-1016.
    PubMed     Text format     Abstract available


    Curr Opin Oncol

  5. SUPPA M, Gandini S
    Sunbeds and melanoma risk: time to close the debate.
    Curr Opin Oncol. 2019 Jan 22. doi: 10.1097/CCO.0000000000000507.
    PubMed     Text format     Abstract available


    Int J Cancer

  6. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  7. ETZKORN JR, Jew OS, Shin TM, Sobanko JF, et al
    Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining for atypical intraepidermal melanocytic proliferation.
    J Am Acad Dermatol. 2018;79:1109-1116.
    PubMed     Text format     Abstract available

  8. MANGOLD AR, Cumsky HJL, Costello CM, Xie DY, et al
    Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study.
    J Am Acad Dermatol. 2018;79:913-920.
    PubMed     Text format     Abstract available

  9. OLANDER J, Miller M, Brown M
    Use of sterile urine cups as sharps containers during Mohs micrographic surgery stages.
    J Am Acad Dermatol. 2018;79:e97-e98.
    PubMed     Text format    

  10. OKHOVAT JP, Beaulieu D, Tsao H, Halpern AC, et al
    The first 30 years of the American Academy of Dermatology skin cancer screening program: 1985-2014.
    J Am Acad Dermatol. 2018;79:884-891.
    PubMed     Text format     Abstract available

  11. STRAZZULLA LC, Li X, Zhu K, Okhovat JP, et al
    Clinicopathologic, misdiagnosis and survival differences between clinically amelanotic melanomas and pigmented melanomas.
    J Am Acad Dermatol. 2019 Jan 14. pii: S0190-9622(19)30082.
    PubMed     Text format     Abstract available

  12. HAWKINS ML, Rioth MJ, Eguchi MM, Cockburn M, et al
    Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.
    J Am Acad Dermatol. 2019 Jan 14. pii: S0190-9622(19)30079.
    PubMed     Text format     Abstract available

  13. BLANK NR, Hibler BP, Tattersall IW, Ensslin CJ, et al
    Melanoma and Melanoma In-Situ Diagnosis after Excision of Atypical Intraepidermal Melanocytic Proliferation (AIMP): A Retrospective Cross-Sectional Analysis.
    J Am Acad Dermatol. 2019 Jan 14. pii: S0190-9622(19)30072.
    PubMed     Text format     Abstract available

  14. HOPKINS ZH, Moreno C, Carlisle R, Secrest AM, et al
    Melanoma prognosis in the United States: Identifying barriers for improved care.
    J Am Acad Dermatol. 2019 Jan 16. pii: S0190-9622(19)30069.
    PubMed     Text format     Abstract available


    J Biol Chem

  15. KHAN Z, Cao DY, Giani JF, Bernstein EA, et al
    Overexpression of the C-domain of angiotensin-converting enzyme reduces melanoma growth by stimulating M1 macrophage polarization.
    J Biol Chem. 2019 Jan 22. pii: RA118.006275. doi: 10.1074/jbc.RA118.006275.
    PubMed     Text format     Abstract available


    J Surg Oncol

  16. RACZ JM, Block MS, Baum CL, Jakub JW, et al
    Management of local or regional non-nodal disease.
    J Surg Oncol. 2019;119:187-199.
    PubMed     Text format     Abstract available

  17. GERKEN ALH, Dobroschke J, Reissfelder C, Hetjens S, et al
    Tissue sealants for the prevention of lymphoceles after radical inguinal lymph node dissection in patients with melanoma: A systematic review and individual patient data meta-analysis.
    J Surg Oncol. 2019 Jan 23. doi: 10.1002/jso.25366.
    PubMed     Text format     Abstract available

  18. BELLO DM
    Indications for the surgical resection of stage IV disease.
    J Surg Oncol. 2019;119:249-261.
    PubMed     Text format     Abstract available

  19. SPILLANE A, Hong A, Fogarty G
    Re-examining the role of adjuvant radiation therapy.
    J Surg Oncol. 2019;119:242-248.
    PubMed     Text format     Abstract available


    Lancet Oncol

  20. DAUD AI
    Revisiting RECIST: the case of treatment beyond progression.
    Lancet Oncol. 2018;19:157-159.
    PubMed     Text format    


    Melanoma Res

  21. GONG HZ, Zheng HY, Li J
    Amelanotic melanoma.
    Melanoma Res. 2019 Jan 21. doi: 10.1097/CMR.0000000000000571.
    PubMed     Text format     Abstract available

  22. RANTALA ES, Hernberg M, Kivela TT
    Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000575.
    PubMed     Text format     Abstract available

  23. JAARSMA-COES MG, Goncalves Ferreira TA, van Haren GR, Marinkovic M, et al
    MRI enables accurate diagnosis and follow-up in uveal melanoma patients after vitrectomy.
    Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000568.
    PubMed     Text format     Abstract available

  24. SACHPEKIDIS C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, et al
    18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
    Melanoma Res. 2018 Nov 1. doi: 10.1097/CMR.0000000000000541.
    PubMed     Text format     Abstract available


    Oncogene

  25. KUMAR R, Njauw CN, Reddy BY, Ji Z, et al
    Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Oncogene. 2019 Jan 16. pii: 10.1038/s41388-018-0632.
    PubMed     Text format     Abstract available

  26. BAGATI A, Moparthy S, Fink EE, Bianchi-Smiraglia A, et al
    KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0689.
    PubMed     Text format     Abstract available

  27. VITIELLO M, Evangelista M, Di Lascio N, Kusmic C, et al
    Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0681.
    PubMed     Text format     Abstract available

  28. MANCUSO P, Tricarico R, Bhattacharjee V, Cosentino L, et al
    Thymine DNA glycosylase as a novel target for melanoma.
    Oncogene. 2019 Jan 23. pii: 10.1038/s41388-018-0640.
    PubMed     Text format     Abstract available


    PLoS One

  29. BASILE MS, Mazzon E, Russo A, Mammana S, et al
    Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
    PLoS One. 2019;14:e0210276.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: